IR-Med (IRME) Operating Leases (2022 - 2025)
IR-Med recorded quarterly Operating Leases of $26000.0 in Q2 2025, down 33.33% quarter-over-quarter from $39000.0 in Q4 2023.
IR-Med's Operating Leases history runs 3 years deep, the most recent figure standing at $26000.0 for Q2 2025.
- In Q2 2025, Operating Leases changed N/A year-over-year to $26000.0; the TTM figure through Jun 2025 stood at $26000.0 (changed N/A YoY), while the FY2023 annual figure was $39000.0, down 2.5% from the prior year.
- Operating Leases came in at $26000.0 for Q2 2025 at IR-Med, down from $39000.0 in the prior quarter.
- In the past five years, Operating Leases ranged from a high of $40000.0 in Q4 2022 to a low of $2000.0 in Q3 2023.
- A 3-year average of $26750.0 and a median of $32500.0 in 2023 frame the typical range for Operating Leases.
- On a YoY basis, Operating Leases climbed as much as 2.5% in 2023 and fell as far as 2.5% in 2023.
- IR-Med's Operating Leases stood at $40000.0 in 2022, then fell by 2.5% to $39000.0 in 2023, then tumbled by 33.33% to $26000.0 in 2025.
- According to Business Quant data, Operating Leases over the past three periods registered $26000.0, $39000.0, and $2000.0 for Q2 2025, Q4 2023, and Q3 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | IR-Med | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 26,000.00 |
| Dec 31, 2023 | 39,000.00 |
| Sep 30, 2023 | 2,000.00 |
| Dec 31, 2022 | 40,000.00 |